首页> Ophthalmology> Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study.

Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study.

导出 LinkOut

翻译打印收藏纠错

第一作者： Ian,Pearce

第一单位： St. Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom. Electronic address: ian.pearce@rlbuht.nhs.uk.

作者： Ian,Pearce ^[1] ; Sanjiv,Banerjee ^[2] ; Ben J L,Burton ^[3] ; Usha,Chakravarthy ^[4] ; Louise,Downey ^[5] ; Richard P,Gale ^[6] ; Jonathan,Gibson ^[7] ; Sergio,Pagliarini ^[8] ; Jignesh,Patel ^[9] ; Sobha,Sivaprasad ^[10] ; Chris,Andrews ^[11] ; Christopher,Brittain ^[12] ; James,Warburton ^[11] ; RELIGHT Study Group

作者单位： St. Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom. Electronic address: ian.pearce@rlbuht.nhs.uk. ^[1] University Hospital of Wales, Cardiff, United Kingdom. ^[2] James Paget University Hospital, Great Yarmouth, United Kingdom. ^[3] Royal Victoria Hospital, Belfast, United Kingdom. ^[4] Hull and East Yorkshire Eye Hospital, Hull, United Kingdom. ^[5] York Teaching Hospital, York, United Kingdom. ^[6] Birmingham Heartlands Hospital, Birmingham, United Kingdom. ^[7] University Hospitals Coventry & Warwickshire, Hospital of St Cross, Rugby, United Kingdom. ^[8] Essex County Hospital, Colchester, United Kingdom. ^[9] Kings College Hospital, London, United Kingdom. ^[10] Novartis Pharmaceuticals UK Ltd., Surrey, United Kingdom. ^[11] F. Hoffmann-La Roche Ltd., Basel, Switzerland. ^[12]